{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:53:29Z","timestamp":1792400009443,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02745-1","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T06:01:41Z","timestamp":1702101701000},"page":"649-658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Matching-Adjusted Indirect Comparison of Recombinant Factor\u00a0IX Albumin Fusion Protein Versus Recombinant Factor\u00a0IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia\u00a0B"],"prefix":"10.1007","volume":"41","author":[{"given":"Benoit","family":"Guillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglass","family":"Drelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Steenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"issue":"1","key":"2745_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45.","journal-title":"Nat Rev Dis Primers"},{"issue":"13","key":"2745_CR2","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","volume":"125","author":"J Oldenburg","year":"2015","unstructured":"Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038\u201344.","journal-title":"Blood"},{"issue":"8","key":"2745_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G. The benefits of prophylaxis in patients with hemophilia\u00a0B. Expert Rev Hematol. 2018;11(8):673\u201383.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2745_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hae.13140","volume":"23","author":"S von Mackensen","year":"2017","unstructured":"von Mackensen S, Eldar-Lissai A, Auguste P, von Maltzahn R, Yu R, Wyrwich KW. Measurement properties of the Haem-A-QoL in haemophilia clinical trials. Haemophilia. 2017;23(3):383\u201391.","journal-title":"Haemophilia"},{"issue":"4","key":"2745_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1365-2516.2001.00534.x","volume":"7","author":"MR Hacker","year":"2001","unstructured":"Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7(4):392\u20136.","journal-title":"Haemophilia"},{"issue":"8","key":"2745_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00228-021-03111-2","volume":"77","author":"T Preijers","year":"2021","unstructured":"Preijers T, Bukkems L, van Spengler M, Leebeek F, Cnossen M, Mathot R. In silico comparison of pharmacokinetic properties of three extended half-life factor\u00a0IX concentrates. Eur J Clin Pharmacol. 2021;77(8):1193\u2013200.","journal-title":"Eur J Clin Pharmacol"},{"issue":"24","key":"2745_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, et al. Phase\u00a03 study of recombinant factor\u00a0IX Fc fusion protein in hemophilia\u00a0B. N Engl J Med. 2013;369(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"14","key":"2745_CR8","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor\u00a0IX albumin fusion protein (rIX-FP) in hemophilia\u00a0B: results of a phase\u00a03 trial. Blood. 2016;127(14):1761\u20139.","journal-title":"Blood"},{"issue":"6","key":"2745_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"issue":"10","key":"2745_CR10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2745_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"2745_CR12","unstructured":"BiogenIdec. Clinical Study Report: B-LONG: an open-label, multi-center evaluation of the safety, pharmacokinetics, and efficacy of recombinant, long-acting coagulation factor IX Fc fusion protein (rFIXFc) in the prevention and treatment of bleeding in previously treated subjects with severe hemophilia B. 2012. Accessed from ema.europa.eu."},{"issue":"1","key":"2745_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v095.i01","volume":"95","author":"A Zeileis","year":"2020","unstructured":"Zeileis A, K\u00f6ll S, Graham N. Various versatile variances: an object-oriented implementation of clustered covariances in R. J Stat Softw. 2020;95(1):1\u201336.","journal-title":"J Stat Softw"},{"key":"2745_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2147\/JBM.S312885","volume":"12","author":"J Astermark","year":"2021","unstructured":"Astermark J, Wojciechowski P, Aballea S, Hakimi Z, Nazir J, Klamroth R. Efficacy of rFIXFc versus rIX-FP for the treatment of patients with hemophilia\u00a0B: matching-adjusted indirect comparison of B-LONG and PROLONG-9FP trials. J Blood Med. 2021;12:613\u201321.","journal-title":"J Blood Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02745-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02745-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T05:16:09Z","timestamp":1707023769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02745-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02745-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Beno\u00eet Guillet has been a consultant for Baxter\/Baxalta\/Shire\/Takeda, BioMarin CSL Behring, Laboratoire Francais du Fractionnement et Des Biotechnologies, Novo Nordisk, Octapharma, Roche-Chuga\u00ef and Swedish Orphan Biovitrum. Songkai Yan, Douglass Drelich, and Radovan Tomic are employees of CSL Behring. Becky Hooper and Jason Steenkamp are employees of EVERSANA who received funding from CSL Behring for conducting the statistical analyses that informed this study. Maria Elisa Mancuso has acted as a consultant for Bayer, BioMarin, CSL Behring, Grifols, Kedrion Biopharma, Laboratoire Francais du Fractionnement et Des Biotechnologies, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Swedish Orphan Biovitrum, Spark Therapeutics, Takeda, and uniQure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on two previously published phase\u00a03 trials (PROLONG-9FP and B-LONG), does not contain any new studies with human participants or animals performed by any of the authors, and thus did not require ethics approval. Both PROLONG-9FP and B-LONG studies were conducted in accordance with the Declaration of Helsinki and local regulations, the protocols were approved by the authorities and the institutional review board\/ethics committee at each participating center, and signed informed consent was obtained from all patients. Informed consent was not required for this analysis given the deidentified nature of the PROLONG-9FP individualized patient-level data and the use of anonymized, previously published data for the B-LONG study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article\u2019s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article\u2019s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Open Access"}}]}}